ReviewFrontiers in transplantation2026
The integration of psychosocial care, ethical governance, and patient-centered research in current and future approaches in the field of vascularized composite allotransplantation.
Review in Frontiers in transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascularized composite allotransplantation (VCA) has transitioned from an experimental endeavor to a clinically viable option for patients with complex tissue loss. While advances in microsurgery, immunosuppression, and perioperative care have improved graft survival, long-term success remains contingent upon psychosocial integration and robust ethical governance. These developments are reshaping not only clinical outcomes but also the conceptual foundations of transplantation. VCA uniquely challenges traditional paradigms, as it is primarily life-enhancing rather than life-saving, thereby intensifying ethical scrutiny regarding risk-benefit proportionality. Psychosocial factors such as identity reconstruction, body wholeness, personal autonomy, adherence, and long-term mental health are central determinants of graft success. Concurrently, innovations such as AI-driven allocation systems, big data analytics, and digital monitoring introduce novel ethical concerns related to autonomy, transparency, data governance, and equity. A key objective of this mini-review is to critically examine how emerging technological innovations in VCA intersect with psychosocial processes and bioethical principles, and to outline a framework for their responsible integration into clinical practice. It argues that technological progress must be embedded within a patient-centered approach that prioritizes lived experience, relational ethics, and trust. The integration of person-centered care models, longitudinal assessments, and interdisciplinary "team science" approaches is essential for ensuring that innovation translates into meaningful, equitable, and ethically sustainable improvements in patient outcomes Ultimately, the future of VCA depends on aligning biomedical innovation with psychosocial resilience and ethical legitimacy, ensuring that reconstructive success translates into meaningful improvements in quality of life and providing access to these transplants for all patients in need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.